The estimated Net Worth of Holdings Ltd. Thermopylae is at least $285 Million dollars as of 29 August 2024. Holdings Thermopylae owns over 283,516 units of AbCellera Biologics stock worth over $150,871,364 and over the last 3 years Holdings sold ABCL stock worth over $134,530,033.
Sign up
Holdings Thermopylae ABCL stock SEC Form 4 insiders trading
Holdings has made over 10 trades of the AbCellera Biologics stock since 2021, according to the Form 4 filled with the SEC. Most recently Holdings bought 283,516 units of ABCL stock worth $739,977 on 29 August 2024.
The largest trade Holdings's ever made was selling 5,598,420 units of AbCellera Biologics stock on 9 June 2021 worth over $134,530,033. On average, Holdings trades about 696,675 units every 98 days since 2021. As of 29 August 2024 Holdings still owns at least 56,086,009 units of AbCellera Biologics stock.
You can see the complete history of Holdings Thermopylae stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Holdings Thermopylae's mailing address?
Holdings's mailing address filed with the SEC is C/O ABCELLERA BIOLOGICS INC, 2215 YUKON STREET, VANCOUVER, A1, .
Insiders trading at AbCellera Biologics
Over the last 4 years, insiders at AbCellera Biologics have traded over $394,042,033 worth of AbCellera Biologics stock and bought 6,630,906 units worth $88,015,834 . The most active insiders traders include Peter Thiel, Andrew Lo, and Holdings Ltd. Thermopylae. On average, AbCellera Biologics executives and independent directors trade stock every 23 days with the average trade being worth of $1,381,181. The most recent stock trade was executed by Holdings Ltd. Thermopylae on 29 August 2024, trading 283,516 units of ABCL stock currently worth $739,977.
What does AbCellera Biologics do?
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
What does AbCellera Biologics's logo look like?
Complete history of Holdings Thermopylae stock trades at AbCellera Biologics
AbCellera Biologics executives and stock owners
AbCellera Biologics executives and other stock owners filed with the SEC include:
-
Tryn T. Stimart Esq., J.D.,
Chief Legal Officer, Chief Compliance Officer & Corp. Sec. -
Dr. Carl L.G. Hansen Ph.D.,
CEO, Pres & Chairperson -
Dr. Carl L. G. Hansen,
Pres, CEO & Director -
Tryn T. Stimart Esq.,
Chief Legal Officer & Corp. Sec. -
Andrew Booth,
Chief Financial Officer -
Caitlin Webster CIPD, M.Sc.,
Sr. Mang. of People & Culture -
Alexandra Weirich M.Sc.,
Mang. of Marketing & Communications -
Murray McCutcheon Ph.D.,
VP of Corp. Devel. -
Tiffany Chiu B.Sc., Ph.D.,
VP of Communications -
Bo Barnhart Ph.D.,
Scientific Director -
Andrew Booth M.B.A.,
Chief Financial Officer -
Dr. Ester Falconer Ph.D.,
Chief Technology Officer -
Dr. Veronique Lecault Ph.D.,
COO & Director -
Veronique Lecault,
Chief Operating Officer -
Tryn Stimart,
Chief Legal Officer -
Michael R Hayden,
Director -
John S. Montalbano,
Director -
Peter Thiel,
Director -
John Hamer,
Director -
Bio, L.P.Bogue Zachary Dcvc...,
-
Andrew Booth,
Chief Financial Officer -
Bio, L.P.Dcvc Bio Gp, Llcjn...,
-
Holdings Ltd. Thermopylae,
10% owner -
Carl L. G. Hansen,
Chief Executive Officer -
Ester Falconer,
Chief Technology Officer